Peringatan Keamanan

Most common adverse reactions (?30%) included fatigue and asthenia, neutropenia, anemia, constipation, nausea, diarrhea, dyspnea, upper-respiratory tract infections, back pain and pyrexia.

Pomalidomide

DB08910

small molecule approved

Deskripsi

Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.

Struktur Molekul 2D

Berat 273.2441
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Healthy subjects = 9.4 hours; Multiple myeloma patients = 7.5 hours.
Volume Distribusi Mean apparent volume of distribution (Vd/F), steady-state = 62 - 138 L
Klirens (Clearance) Total body clearance = 7-10 L/hour

Absorpsi

Pomalidomide is generally well absorbed. The major circulating component is the parent compound. Tmax, single oral dose = 2 -3 hours. When 4 mg of promalidomide is given to patients with multiple myeloma, the steady-state pharmacokinetic parameters are as follows: AUC(T) = 400 ng.hr/mL; Cmax = 75 ng/mL. Promalidomide accumulates following multiple doses.

Metabolisme

Promalidomide is hepatically metabolized by CYP1A2 and CYP3A4. The metabolites are 26-fold less active than the parent compound. Minor contributions from CYP2C19 and CYP2D6 have been observed in vitro.

Rute Eliminasi

When a single oral dose (2mg) is given to healthy subjects, 73% of the dose was eliminated in urine. 15% of the dose was eliminated in feces. 2% and 8% of the dose eliminated unchanged as pomalidomide in urine and feces, respectively.

Interaksi Makanan

2 Data
  • 1. Take at the same time every day.
  • 2. Take with or without food. Administration of pomalidomide with food reduces the AUC and Cmax by 8% and 27%, respectively, and delays Tmax by two and a half hours.

Interaksi Obat

2147 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Pomalidomide.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Pomalidomide.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Pomalidomide.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Pomalidomide.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Pomalidomide.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Pomalidomide.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Pomalidomide.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Pomalidomide.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Pomalidomide.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Pomalidomide.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Pomalidomide.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Pomalidomide.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Pomalidomide.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Pomalidomide.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Pomalidomide.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pomalidomide.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Pomalidomide.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Pomalidomide.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Pomalidomide.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Pomalidomide.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Pomalidomide.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Pomalidomide.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Pomalidomide.
Cladribine Pomalidomide may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Pomalidomide.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Pomalidomide.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Pomalidomide.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Pomalidomide.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Pomalidomide.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Pomalidomide.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Pomalidomide.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Pomalidomide.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Pomalidomide.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Pomalidomide.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Pomalidomide.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Pomalidomide.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Pomalidomide.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Pomalidomide.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Pomalidomide.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Pomalidomide.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Pomalidomide.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Pomalidomide.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Pomalidomide.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Pomalidomide.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Pomalidomide.
Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Pomalidomide.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Pomalidomide.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Pomalidomide.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Pomalidomide.
Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Pomalidomide.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Pomalidomide.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Pomalidomide.
Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Pomalidomide.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Pomalidomide.
Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Pomalidomide.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Pomalidomide.
Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Pomalidomide.
Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Pomalidomide.
Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Pomalidomide.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Pomalidomide.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Pomalidomide.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Pomalidomide.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Pomalidomide.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Pomalidomide.
Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Pomalidomide.
Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Pomalidomide.
Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Pomalidomide.
Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Pomalidomide.
Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pomalidomide.
Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Pomalidomide.
Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Pomalidomide.
Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Pomalidomide.
Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Pomalidomide.
Capecitabine The risk or severity of adverse effects can be increased when Capecitabine is combined with Pomalidomide.
Trilostane The risk or severity of adverse effects can be increased when Trilostane is combined with Pomalidomide.
Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Pomalidomide.
Idarubicin The risk or severity of adverse effects can be increased when Idarubicin is combined with Pomalidomide.
Estramustine The risk or severity of adverse effects can be increased when Estramustine is combined with Pomalidomide.
Lomustine The risk or severity of adverse effects can be increased when Lomustine is combined with Pomalidomide.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Pomalidomide.
Decitabine The risk or severity of adverse effects can be increased when Decitabine is combined with Pomalidomide.
Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Pomalidomide.
Ciclesonide The risk or severity of adverse effects can be increased when Ciclesonide is combined with Pomalidomide.
Stepronin The risk or severity of adverse effects can be increased when Stepronin is combined with Pomalidomide.
Hydroxychloroquine The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Pomalidomide.
Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Pomalidomide.
Vorinostat The risk or severity of adverse effects can be increased when Vorinostat is combined with Pomalidomide.
2-Methoxyethanol The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Pomalidomide.
Brequinar The risk or severity of adverse effects can be increased when Brequinar is combined with Pomalidomide.
Thiotepa The risk or severity of adverse effects can be increased when Thiotepa is combined with Pomalidomide.
Aldosterone The risk or severity of adverse effects can be increased when Aldosterone is combined with Pomalidomide.
Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Pomalidomide.
Belinostat The risk or severity of adverse effects can be increased when Belinostat is combined with Pomalidomide.
Trabectedin The risk or severity of adverse effects can be increased when Trabectedin is combined with Pomalidomide.
Interferon alfa The risk or severity of adverse effects can be increased when Interferon alfa is combined with Pomalidomide.
Glatiramer The risk or severity of adverse effects can be increased when Glatiramer is combined with Pomalidomide.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Pomalidomide.
Human interferon omega-1 The risk or severity of adverse effects can be increased when Human interferon omega-1 is combined with Pomalidomide.
Panobinostat The risk or severity of adverse effects can be increased when Panobinostat is combined with Pomalidomide.
Mepolizumab The risk or severity of adverse effects can be increased when Mepolizumab is combined with Pomalidomide.

Target Protein

Protein cereblon CRBN
Tumor necrosis factor TNF
Prostaglandin G/H synthase 2 PTGS2

Referensi & Sumber

Artikel (PubMed)
  • PMID: 22917017
    Gertz MA: Pomalidomide and myeloma meningitis. Leuk Lymphoma. 2013 Apr;54(4):681-2. doi: 10.3109/10428194.2012.723708. Epub 2013 Jan 2.
  • PMID: 23730498
    McCurdy AR, Lacy MQ: Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist. Ther Adv Hematol. 2013 Jun;4(3):211-6. doi: 10.1177/2040620713480155.
  • PMID: 23690693
    Terpos E, Kanellias N, Christoulas D, Kastritis E, Dimopoulos MA: Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. Onco Targets Ther. 2013 May 10;6:531-8. doi: 10.2147/OTT.S34498. Print 2013.

Contoh Produk & Brand

Produk: 56 • International brands: 0
Produk
  • Apo-pomalidomide
    Capsule • 1 mg • Oral • Canada • Generic • Approved
  • Apo-pomalidomide
    Capsule • 2 mg • Oral • Canada • Generic • Approved
  • Apo-pomalidomide
    Capsule • 3 mg • Oral • Canada • Generic • Approved
  • Apo-pomalidomide
    Capsule • 4 mg • Oral • Canada • Generic • Approved
  • Imnovid
    Capsule • 1 mg • Oral • EU • Approved
  • Imnovid
    Capsule • 2 mg • Oral • EU • Approved
  • Imnovid
    Capsule • 3 mg • Oral • EU • Approved
  • Imnovid
    Capsule • 4 mg • Oral • EU • Approved
Menampilkan 8 dari 56 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul